Latest Daily News

More Stories

May 17, 2018

Pilot Study of an Internet-based Self-Management Program for Symptom Control in Patients With Early Stage Breast Cancer.

Read more

May 15, 2018

Gabriel N. Hortobagyi, MD, FACP, FASCO, is the recipient of the 2018 Gianni Bonadonna Breast Cancer Award for his leadership and contribution in the field of translational medicine in breast cancer, with an exceptional record of mentorship.

Read more

May 14, 2018

During the 2012 ASCO Annual Meeting Plenary Session, Kimberly L. Blackwell, MD, of Duke University Medical Center, presented the primary results of the EMILIA trial.

Read more

May 13, 2018

The treatment paradigm of breast cancer has celebrated the successes of targeted therapy for decades. Currently, the hormone receptor and HER2 statuses of a breast tumor continue to drive the selection of therapy for patients with early-stage breast cancer and metastatic breast cancer (mBC).

Read more

May 11, 2018

Megan Kruse, MD, and Jame Abraham, MD, FACP, answer a question posed by an attendee during a Best of ASCO® Meeting.

Read more

May 11, 2018

Sayeh Lavasani, MD, MSc, FRCPC, answers a question posed by an attendee during a Best of ASCO® Meeting.

Read more

June 5, 2017

Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to chemotherapy and trastuzumab.

Read more
June 5, 2017

The safety and efficacy of trastuzumab biosimilars for neoadjuvant breast cancer therapy demonstrated comparable safety and efficacy, according to two studies.

Read more
June 5, 2017

Results from the Short-HER study suggest a shorter course may reduce the rate of severe cardiac toxicity.

Read more

June 4, 2017

Olaparib tablet monotherapy yielded improved progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a germline BRCA mutation.

Read more

June 3, 2017

Abemaciclib combined with the estrogen inhibitor fulvestrant may significantly reduce the risk of disease progression and increase the objective response rate in women with metastatic breast cancer, according to the results of the MONARCH 2 study.

Read more
June 3, 2017

Two studies presented during the 2017 ASCO Annual Meeting provided additional evidence of the efficacy and safety of the CDK4/6 inhibitor ribociclib plus letrozole as a first-line treatment for ER-positive/HER2-negative advanced breast cancer. 

Read more
June 1, 2017

Kelly Cares Foundation recently became one of the newest supporters of the Conquer Cancer Foundation Young Investigator Award program.

Read more
May 25, 2017

Tufia C. Haddad, MD, and Matthew P. Goetz, MD, answer a question posed by an attendee during a Best of ASCO Meeting about treating ER-positive, HER2-negative metastatic breast cancer.

Read more
May 25, 2017

Eric P. Winer, MD, FASCO, of Dana-Farber Cancer Institute, is the winner of the 2017 Gianni Bonadonna Breast Cancer Award and Lecture.

Read more

May 25, 2017

Consensus guidelines on the minimal necessary margin width in the setting of breast-conserving surgery margins have great potential to increase standardization of practice and reduce morbidity and cost; however, we must be careful not to fall into the trap of practicing “cookbook medicine.”

Read more
May 25, 2017

Authors discuss the evolution of the liquid biopsy in the detection and treatment of breast cancer.

Read more
June 6, 2016

A large study found that the individual surgeon and the institution exert greater influence on whether patients undergo mastectomy versus lumpectomy compared with all other clinical and demographic variables, except for tumor size and nodal status.

Read more
June 6, 2016

Results from the phase III ETNA study concluded there was no statistical difference in the pCR rate between neoadjuvant nab-paclitaxel and paclitaxel both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

Read more
June 6, 2016

Extending aromatase inhibitor therapy beyond the standard 5 years out to 10 years for postmenopausal women with HR-positive early breast cancer significantly improves disease-free survival over placebo.

Read more